Clinical Obesity最新文献_第3页

Outcomes of Endoscopic Sleeve Gastroplasty (ESG) at a Single Institution: The First Report on Weight Loss and Complication Rates in Japan 内镜下套管胃成形术（ESG）在单一机构的结果：日本体重减轻和并发症发生率的第一份报告。

IF 2.1

Clinical Obesity Pub Date : 2025-11-08 DOI: 10.1111/cob.70053

Kodai Takahashi

{"title":"Outcomes of Endoscopic Sleeve Gastroplasty (ESG) at a Single Institution: The First Report on Weight Loss and Complication Rates in Japan","authors":"Kodai Takahashi","doi":"10.1111/cob.70053","DOIUrl":"10.1111/cob.70053","url":null,"abstract":"<div>\u0000 \u0000 <p>Endoscopic sleeve gastroplasty (ESG) has gained recognition as a minimally invasive endoscopic treatment for obesity; however, clinical data in Japan is lacking. A retrospective review was conducted of 91 individuals with obesity who underwent ESG between January 2023 and November 2024. Eligibility included BMI ≥ 27.5 with at least one obesity-related comorbidity and preference for non-surgical therapy. Primary outcomes were the percentage of total weight loss (%TWL) at 1 month, 6 months and 1 year, and the rate of complications. The mean %TWL was 10.1% at 1 month, 15.2% at 6 months and 19.8% at 1 year. The follow-up completion rates were 100% at 1 month, 96.7% at 6 months and 87.9% at 12 months. Improvement in obesity-related comorbidities was observed in 57.1% of individuals with hypertension, 94.7% with dyslipidemia, 91.7% with diabetes, 96.9% with fatty liver disease and 75.0% with obstructive sleep apnea. One adverse event (1.1%) occurred, a pyriform sinus injury that resolved with conservative management; no severe complications were observed. ESG demonstrated favourable short-term weight loss and safety outcomes in Japan. These findings suggest ESG as a viable treatment option for Japanese individuals with obesity.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145470782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of the 2025 Lancet Diagnostic Criteria on Obesity Treatment in the United States 2025年柳叶刀诊断标准对美国肥胖治疗的影响。

IF 2.1

Clinical Obesity Pub Date : 2025-11-05 DOI: 10.1111/cob.70050

Maryna Chumakova, Francis M. Finucane, Yi-Jun Chen, Yen-Yi Juo

{"title":"Impact of the 2025 Lancet Diagnostic Criteria on Obesity Treatment in the United States","authors":"Maryna Chumakova, Francis M. Finucane, Yi-Jun Chen, Yen-Yi Juo","doi":"10.1111/cob.70050","DOIUrl":"10.1111/cob.70050","url":null,"abstract":"<div>\u0000 \u0000 <p>For decades, clinicians have diagnosed obesity using body mass index (BMI). In January 2025, the updated Lancet guideline recommended the use of anthropometric index in addition to BMI. It also recommended routine treatment for clinical obesity, that is those with organ dysfunction or activity limitations, but for preclinical obesity, only treatment based on individual risk–benefit assessment. The objective of this study is to evaluate how the guideline could change obesity management on a national level. In this cross-sectional study, we projected the 2025 Lancet guideline onto the 2021–2023 National Health and Nutrition Examination Survey (NHANES), a nationally representative population survey. We characterised the change in treatment recommendation that would occur if the Lancet guideline replaced current treatment guidelines. According to the Lancet guideline, the national prevalence of obesity was about 39.6 (1.8) %. The addition of the anthropometric index did not alter obesity diagnosis in most participants, as 96.8 (0.5) % of participants with a BMI > 30 kg/m<sup>2</sup> also had elevated waist circumference. Approximately 80.3 (1.2) % of participants with obesity were classified as having clinical obesity. There is a large discrepancy between current medical guidelines and the Lancet guideline. Approximately 41.3% ± 1.2% of people who fit the indication for pharmaceutical treatment do not have clinical obesity, according to the Lancet guideline. Although the Lancet guideline would not alter obesity diagnosis for most people, it would encourage providers to take a more individual-based and multi-organ approach to managing obesity.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Relationship Between Obesity, Weight Loss and Health-Related Quality of Life: An Updated Systematic Review of Reviews 探讨肥胖、体重减轻和健康相关生活质量之间的关系：一项最新的系统综述。

IF 2.1

Clinical Obesity Pub Date : 2025-11-03 DOI: 10.1111/cob.70049

Tone Nygaard Flølo, Hui-Hsuan Liu, John Roger Andersen, Ronette L. Kolotkin

{"title":"Exploring the Relationship Between Obesity, Weight Loss and Health-Related Quality of Life: An Updated Systematic Review of Reviews","authors":"Tone Nygaard Flølo, Hui-Hsuan Liu, John Roger Andersen, Ronette L. Kolotkin","doi":"10.1111/cob.70049","DOIUrl":"10.1111/cob.70049","url":null,"abstract":"<p>The aim of this systematic literature review (SLR) of reviews was to update the evidence, established in a 2017 SLR, on the impact of obesity and weight loss by various interventions on health-related quality of life (HRQoL). In total, eight SLRs and/or meta-analyses published since 2017 were identified. The results consistently demonstrated a negative association between obesity and HRQoL, with some evidence suggesting poorer HRQoL in people with adverse metabolic profiles. In addition to substantial weight or body mass index reduction, metabolic and bariatric surgery (MBS) or endoscopic bariatric therapies resulted in significant and clinically relevant HRQoL improvements, with pronounced and persistent effects on the physical components in particular. HRQoL typically improved within 1–2 years after MBS and stabilised or deteriorated while remaining above baseline in subsequent years, likely due to weight regain. Evidence for the benefits of exercise interventions on HRQoL was inconclusive. Notably, no SLRs on anti-obesity medications were identified, limiting conclusions on this emerging treatment area. This updated SLR expands on previous findings from the 2017 SLR, providing additional insights into underexplored areas, including the role of metabolic profiles in HRQoL and trends of HRQoL after MBS. Evidence synthesis remains challenging due to heterogeneity in HRQoL measurements used in this field.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Effect of a Hospital-Based Intervention Program on BMI Trajectories in Danish Children and Adolescents With Overweight and Obesity: A 6-Year Follow-Up 基于医院的干预方案对丹麦超重和肥胖儿童和青少年BMI轨迹的长期影响：6年随访

IF 2.1

Clinical Obesity Pub Date : 2025-11-02 DOI: 10.1111/cob.70052

Mette Fogh, Jane Nautrup Østergaard, Rasmus Møller Jørgensen, Eeva-Liisa Røssell, Marianne Eg, Helle Terkildsen Maindal, Gunnar Toft, Henrik Støvring, Jens Meldgaard Bruun

{"title":"Long-Term Effect of a Hospital-Based Intervention Program on BMI Trajectories in Danish Children and Adolescents With Overweight and Obesity: A 6-Year Follow-Up","authors":"Mette Fogh, Jane Nautrup Østergaard, Rasmus Møller Jørgensen, Eeva-Liisa Røssell, Marianne Eg, Helle Terkildsen Maindal, Gunnar Toft, Henrik Støvring, Jens Meldgaard Bruun","doi":"10.1111/cob.70052","DOIUrl":"10.1111/cob.70052","url":null,"abstract":"<div>\u0000 \u0000 <p>Childhood obesity is associated with adverse health and psychosocial outcomes, often persisting into adulthood. Hospital-based lifestyle interventions may provide intensive support, but evidence on long-term effectiveness is limited. To evaluate changes in Body Mass Index z-score (BMIz) among children and adolescents with overweight and obesity participating in a hospital-based intervention compared to matched controls. This matched prospective cohort study includes children and adolescents aged 5–15 years. The intervention consisted of a family-centered hospital-based lifestyle program focusing on diet, physical activity, sleep and screen time management. Controls were matched on age, sex, weight category, and calendar year. BMI trajectories were analyzed using mixed effects models with linear splines, adjusting for socioeconomic factors from national registries. A total sample size of 1897 children and adolescents was included (325 intervention, 1572 controls). The intervention group achieved a higher reduction in BMIz during the first 6 months (−0.74 SD/years, 95% CI: −0.89; −0.60) and up to 12 months (−0.31 SD/years, −0.45; −0.16), compared to controls. From 12 to 36 months, a rebound in BMIz occurred (0.14, SD/years, 0.10; 0.17), and continued to rise through 72 months. The intervention was associated with improvements in BMIz up to 12 months after the intervention. However, the effects were not sustained at 6 years of follow-up.</p>\u0000 <p><b>Trial Registration:</b> Clinicaltrials.Gov identifier: NCT05790174</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alcohol Use After Bariatric Surgery: A Comprehensive Review of Current Knowledge and Research Gaps 减肥手术后的酒精使用：对当前知识和研究差距的全面回顾

IF 2.1

Clinical Obesity Pub Date : 2025-10-28 DOI: 10.1111/cob.70048

Esin Er, Cécile Flahault, Anne-Marie Etienne

{"title":"Alcohol Use After Bariatric Surgery: A Comprehensive Review of Current Knowledge and Research Gaps","authors":"Esin Er, Cécile Flahault, Anne-Marie Etienne","doi":"10.1111/cob.70048","DOIUrl":"10.1111/cob.70048","url":null,"abstract":"<div>\u0000 \u0000 <p>In recent years, there has been increased research on alcohol consumption following bariatric surgery. This review aimed to synthesise existing quantitative research on this topic and identify knowledge gaps in the literature. A comprehensive search was performed across Medline, PsychInfo and Scopus. Studies involving human participants who underwent bariatric surgery and reporting postoperative alcohol consumption were considered. A total of 88 studies were included. Overall, most longitudinal studies found an increased prevalence of problematic alcohol consumption (PAC) post-surgery. Risk factors for postoperative PAC remain poorly understood. Explanatory hypotheses include addiction transfer theory, changes in alcohol pharmacokinetics, and increased rewarding effects of alcohol postoperatively. While the addiction transfer theory lacks empirical support, further research is needed to understand how alterations in alcohol metabolism may lead to problematic consumption in some cases. We found only one study on alcohol's rewarding effects post-surgery. Regarding the consequences of PAC, body weight seems unaffected while alcohol-related hospitalizations, liver disease and mortality post-surgery are all increased. Few studies referred to interventions aiming to prevent or treat PAC postoperatively. In conclusion, while the increase in PAC prevalence after bariatric surgery is well documented, substantial knowledge gaps remain regarding its risk factors, underlying mechanisms, potential consequences and the development of prevention and treatment strategies.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145387487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Removing Barriers to Bariatric Surgery: The Role of Intellectual and Developmental Disabilities on Outcomes in Adolescents and Young Adults 消除减肥手术的障碍：智力和发育障碍在青少年和年轻人预后中的作用。

IF 2.1

Clinical Obesity Pub Date : 2025-10-13 DOI: 10.1111/cob.70047

Fiona Beltran, Alyssa Stetson, Christa Bizimana, Michael Kochis, Cornelia Griggs

{"title":"Removing Barriers to Bariatric Surgery: The Role of Intellectual and Developmental Disabilities on Outcomes in Adolescents and Young Adults","authors":"Fiona Beltran, Alyssa Stetson, Christa Bizimana, Michael Kochis, Cornelia Griggs","doi":"10.1111/cob.70047","DOIUrl":"10.1111/cob.70047","url":null,"abstract":"<div>\u0000 \u0000 <p>Metabolic and bariatric surgery (MBS) is an effective means of achieving weight loss for adolescents and young adults (AYA) with obesity. Intellectual and developmental disabilities (IDD) are not absolute contraindications for MBS treatment in AYA with obesity. We sought to determine whether a diagnosis of IDD is associated with weight loss after MBS. We conducted a retrospective chart review of patients ≤ 21 years who underwent MBS at a single institution, comparing outcomes among those with IDD and those without. A total of 103 patients were included. Nine were diagnosed with IDD preoperatively: two had Autism, two had Down Syndrome and five had unspecified IDD. Preoperative BMI was comparable in patients with IDD and those without. Postoperative weight loss was equivalent between AYA with and without IDD at 12 (24.7% vs. 28.9%), 24 (30.9% vs. 25.1%) and 36 months (25.3% vs. 20.8%). At 12 months, four non-IDD patients were deficient in B1, B12 or iron, while no patients with IDD were deficient in any micronutrients. AYA patients with IDD may derive equal weight loss benefit from MBS with comparable micronutrient status. Barriers to MBS in AYA with IDD need to be addressed to expand obesity treatment.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes 在两个商业减肥计划中早期体重减轻和其他与临床显著体重减轻相关的因素。

IF 2.1

Clinical Obesity Pub Date : 2025-10-11 DOI: 10.1111/cob.70046

Christopher D. Coleman, Jessica R. Kiel, Orsolya M. Palacios, Marjorie Bell, Meredith L. Wilcox, Kevin C. Maki, Jessica L. Unick, Satya S. Jonnalagadda

{"title":"Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes","authors":"Christopher D. Coleman, Jessica R. Kiel, Orsolya M. Palacios, Marjorie Bell, Meredith L. Wilcox, Kevin C. Maki, Jessica L. Unick, Satya S. Jonnalagadda","doi":"10.1111/cob.70046","DOIUrl":"10.1111/cob.70046","url":null,"abstract":"<p>This secondary analysis assessed potential factors associated with achieving ≥ 5% or ≥ 10% weight loss among adults in a clinical trial evaluating two commercial weight loss programmes. Participants [<i>n</i> = 124, 45.7 (13.1) years, 20.2% male, BMI 34.4 (3.4) kg/m<sup>2</sup>] were randomised to the Medifast or OPTAVIA weight loss programme, both of which included meal replacements and behavioural support. Multivariable logistic regression analyses were used to assess early weight loss thresholds (percent weight loss at 2 and 4 weeks) and potential demographic, anthropometric, behavioural, and lifestyle factors associated with ≥ 5% or ≥ 10% weight loss at 16 weeks. Age, education, ≥ 1% weight loss by Week 2, ≥ 2% weight loss by Week 4, number of support contacts and programme adherence through Week 4 were significantly (<i>p</i> < 0.05) associated with achieving ≥ 5% weight loss. Participants losing ≥ 2% by Week 4 had 24.6 (95% CI: 2.49, 243) times greater odds of losing ≥ 5% by Week 16. For ≥ 10% weight loss at 16 weeks, positive factors associated included age, assignment to the OPTAVIA programme, ≥ 3% weight loss by Week 4 and programme adherence through Week 4 (<i>p</i> < 0.05). Participants losing ≥ 3% by Week 4 had 19.4 (95% CI: 2.02, 186) times greater odds of losing ≥ 10%. While several variables were significantly associated with achieving clinically significant weight loss, 4-week weight loss was strongest. These results may be useful for early identification of individuals at risk for failing to achieve clinically significant weight loss who may benefit from intensification of counselling to assist in attaining weight loss goals.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England 西马鲁肽在整个英格兰治疗肥胖和超重的调试差异：英格兰42个综合护理委员会的三个基于信息的自由测绘练习的结果。

IF 2.1

Clinical Obesity Pub Date : 2025-09-11 DOI: 10.1111/cob.70044

Anne de Bray, Hanna Schnitzer, Elisabeth Mahase, Puspha Singh, Rob Andrews, Barbara M. McGowan, Sarah Le Brocq, John P. H. Wilding, Stuart W. Flint, Jonathan M. Hazlehurst

{"title":"Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England","authors":"Anne de Bray, Hanna Schnitzer, Elisabeth Mahase, Puspha Singh, Rob Andrews, Barbara M. McGowan, Sarah Le Brocq, John P. H. Wilding, Stuart W. Flint, Jonathan M. Hazlehurst","doi":"10.1111/cob.70044","DOIUrl":"10.1111/cob.70044","url":null,"abstract":"<p>Obesity medications are recommended in England with legislation necessitating their availability. However, given the number of people who meet clinically approved eligibility criteria, funding these medications and associated support services may limit efficacy at a population health level. This study aimed to assess the commissioning and availability of services and obesity medications across England. Three sets of freedom of information requests were sent to the 42 ICBs in England by Sky News Ltd, The BMJ and the study investigators of this work with questions focused on commissioning of services and medication eligibility and prescription across England. The three data sets were combined to provide a narrative description to inform further development in obesity care. The availability of services across England was partial, and when services did exist, medication access was limited by funding and more restrictive eligibility criteria beyond those approved by the National Institute of Health and Care Excellence. Subsequently, very few patients receive NHS prescriptions even in areas where funding medications are reportedly available. The capacity of services to offer comprehensive care for patients to receive obesity medications is insufficient to meet current demand. Despite legislation for the delivery of obesity medications, these treatment options are not widely available on the NHS. There is insufficient service capacity to provide comprehensive care for eligible patients seeking obesity medications as a treatment option.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission's Obesity Framework and King's Obesity Staging System 超越BMI：临床医生整合柳叶刀委员会肥胖框架和国王肥胖分期系统的实用指南。

IF 2.1

Clinical Obesity Pub Date : 2025-09-09 DOI: 10.1111/cob.70045

Tak Ying Louise Ko, Alexander D. Miras, Dimitri J. Pournaras, Carel W. Le Roux

引用次数: 0

Measuring and Managing Obesity in Pregnancy Using the Edmonton Obesity Staging System: A Scoping Review 使用埃德蒙顿肥胖分期系统测量和管理妊娠期肥胖：范围综述。

IF 2.1

Clinical Obesity Pub Date : 2025-08-28 DOI: 10.1111/cob.70043

Taniya S. Nagpal, Jordyn M. Cox, Ximena Ramos Salas, Kristi B. Adamo

{"title":"Measuring and Managing Obesity in Pregnancy Using the Edmonton Obesity Staging System: A Scoping Review","authors":"Taniya S. Nagpal, Jordyn M. Cox, Ximena Ramos Salas, Kristi B. Adamo","doi":"10.1111/cob.70043","DOIUrl":"10.1111/cob.70043","url":null,"abstract":"<p>Emerging evidence and clinical practice guidelines have highlighted that obesity, defined as a chronic disease characterised by excess or dysfunctional adipose tissue, may not be accurately measured or understood by solely relying on body mass index (BMI) which is a measure of size not functionality. An alternative to BMI, as proposed in the Canadian Adult Obesity Management Guideline, is the use of the Edmonton Obesity Staging System (EOSS). While the EOSS has been evaluated in both adult and paediatric populations, pregnant individuals remain an underrepresented clinical group in its application. Prenatal care relies on BMI for measurement of maternal obesity; however, the EOSS may be an adjunct or alternative method to consider. This scoping review aimed to summarise previous research on EOSS in pregnancy and to advise future directions. Only three cohort studies were identified, emphasising a critical gap in obesity research. Both BMI and higher EOSS stages (i.e., 3 and 4) were associated with prenatal complications (e.g., preeclampsia, venous thromboembolism, wound complications). Given that EOSS has been used in other populations and is noted to be an effective patient-centred tool to diagnose and manage obesity, future work may explore its use in pregnancy both in comparison to and in conjunction with BMI.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0